BACKGROUND: Extended-spectrum beta-lactamase (ESBL)-producing organisms, first identified in Germany in 1983, are now widely recognized as clinically relevant causes of infections in community. METHODS: Our objective was to evaluate the clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase (CO-ESBL)-producing Escherichia coli infections. We used a case-case-control study undertaken in a 450-bed, tertiary care hospital. Patients included case group (CG) I, which had confirmed CO-ESBL-producing E coli infections (n=46). Case group (CG) II (n=46) included patients with CO-non-ESBL-producing E coli infections. Controls (n=138) were patients without infections. RESULTS: By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II. Patients with CO-ESBL in CG I versus controls were more likely to die (30% vs 0%, respectively; P< .001), had prolonged hospital length of stay (8 vs 5 days, respectively; P< .001), and had higher hospitalization costs (median, US $528 vs $108, respectively; P< .001). The plasmid carrying the CTX-M-15 gene was identified in 13 of 25 (52%) available CO-ESBL-producing E coli isolates. CONCLUSION: CO-ESBL-producing E coli is an emerging multidrug-resistant microorganism in Thailand. Patients with prior ESBL colonization and recent antibiotic exposures, especially to third-generation cephalosporins and fluoroquinolones, were at risk for CO-ESBL-producing E coli infection.
BACKGROUND: Extended-spectrum beta-lactamase (ESBL)-producing organisms, first identified in Germany in 1983, are now widely recognized as clinically relevant causes of infections in community. METHODS: Our objective was to evaluate the clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase (CO-ESBL)-producing Escherichia coli infections. We used a case-case-control study undertaken in a 450-bed, tertiary care hospital. Patients included case group (CG) I, which had confirmed CO-ESBL-producing E coli infections (n=46). Case group (CG) II (n=46) included patients with CO-non-ESBL-producing E coli infections. Controls (n=138) were patients without infections. RESULTS: By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II. Patients with CO-ESBL in CG I versus controls were more likely to die (30% vs 0%, respectively; P< .001), had prolonged hospital length of stay (8 vs 5 days, respectively; P< .001), and had higher hospitalization costs (median, US $528 vs $108, respectively; P< .001). The plasmid carrying the CTX-M-15 gene was identified in 13 of 25 (52%) available CO-ESBL-producing E coli isolates. CONCLUSION: CO-ESBL-producing E coli is an emerging multidrug-resistant microorganism in Thailand. Patients with prior ESBL colonization and recent antibiotic exposures, especially to third-generation cephalosporins and fluoroquinolones, were at risk for CO-ESBL-producing E coli infection.
Authors: Joshua T Thaden; Yanhong Li; Felicia Ruffin; Stacey A Maskarinec; Jonathan M Hill-Rorie; Lisa C Wanda; Shelby D Reed; Vance G Fowler Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191
Authors: Yohei Doi; Yoon Soo Park; Jesabel I Rivera; Jennifer M Adams-Haduch; Ameet Hingwe; Emilia M Sordillo; James S Lewis; Wanita J Howard; Laura E Johnson; Bruce Polsky; James H Jorgensen; Sandra S Richter; Kathleen A Shutt; David L Paterson Journal: Clin Infect Dis Date: 2012-11-13 Impact factor: 9.079
Authors: Judith A Anesi; Ebbing Lautenbach; Irving Nachamkin; Charles Garrigan; Warren B Bilker; Mary Wheeler; Pam Tolomeo; Jennifer H Han Journal: Infect Control Hosp Epidemiol Date: 2016-09-28 Impact factor: 3.254
Authors: Hanna E Sidjabat; David L Paterson; Jennifer M Adams-Haduch; Lindsay Ewan; Anthony W Pasculle; Carlene A Muto; Guo-Bao Tian; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2009-08-17 Impact factor: 5.191
Authors: Anne J Blaschke; E Kent Korgenski; Judy A Daly; Bonnie LaFleur; Andrew T Pavia; Carrie L Byington Journal: Am J Infect Control Date: 2009-01-19 Impact factor: 2.918
Authors: Judith A Anesi; Ebbing Lautenbach; Irving Nachamkin; Charles Garrigan; Warren B Bilker; Jacqueline Omorogbe; Lois Dankwa; Mary K Wheeler; Pam Tolomeo; Jennifer H Han Journal: Infect Control Hosp Epidemiol Date: 2018-10-30 Impact factor: 3.254